Keywords
Uterine Cervical Neoplasms
Mass Vaccination
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To present scientific works that show the impact of quadrivalent vaccination against HPV in the decrease in the incidence of cervical cancer; as a way of ratifying the importance of primary prevention in one of the main public health problems in women’s health. Bibliographic review: Cervical cancer is responsible for a significant number of deaths in women of different age groups in different parts of the world. Its occurrence has been widely associated with Human Papillomavirus (HPV) infection, which causes an excessive rate of cell replication with tumor evolution. However, with the advent of vaccines for some HPV genotypes, the number of cases of cervical cancer associated with this infection has drastically reduced, especially in developing countries. The vaccines currently available in the world comprise bivalent, quadrivalent and nineth-valent. In Brazil, after the inclusion of HPV vaccination in the National Immunization Program in 2014, there was a reduction in the number of diagnosed cervical cancer cases. Final considerations: The works presented lead to the conclusion that vaccination against HPV is effective in reducing the incidence of pre-neoplastic lesions related to cervical cancer; which contributes to the reduction of morbidity and mortality of previously vaccinated women.
References
ALVARENGA SP, et al. Vacina contra o HPV: avaliando as contradições da indicação e posologia atual. Revista da Universidade Vale do Rio Verde, 2016; 14(2): 395-402.
ARBYN M, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews, 2018; (5).
ATHANASIOU A, et al. HPV vaccination and cancer prevention. Best Pract Res Clin Obstet Gynaecol, 2020; 65: 109-124.
BORSATTO AZ, et al. Vacina contra o HPV e a Prevenção do Câncer do Colo do Útero: Subsídios para a Prática. Revista Brasileira de Cancerologia, 2011; 57(1): 67-74.
BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Coordenação Geral do Programa Nacional de Imunizações. Guia Prático sobre o HPV - Perguntas e Respostas. 2013. Disponível em: http://drguilhermeleme.com.br/wp-content/uploads/2016/01/Guia_Pratico_HPV_Perguntas_e_Respostas.pdf. Acesso em 12 set. 2022.
BRAY F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018; 68(6): 394-424.
BROTHERTON JM, et al. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. Papillomavirus Research, 2019; 8: 100-177.
CALUMBY RJN, et al. Papiloma Vírus Humano (HPV) e neoplasia cervical: importância da vacinação / Human papillomavirus (HPV) and cervical neoplasia: importance of vaccination. Brazilian Journal of Health Review, 2020; 3(2): 1610-1628.
CARVALHO KF, et al. A relação entre HPV e Câncer de Colo de Útero: um panorama a partir da produção bibliográfica da área. Revista Saúde em Foco, 2019; 11: 264-278.
GILIO AE. Manual de Imunizações: Centro de Imunizações Hospital Israelita Albert Einstein. 4ª ed. Rio de Janeiro: Elsevier, 2009; 80p.
GUIMARÃES MVMB, et al. Resposta imune ao HPV e as neoplasias intra-epiteliais cervicais em mulheres infectadas e não infectadas pelo HIV: perfil de citocinas. Femina, 2011; 39(5): 275-280.
HERWEIJER E, et al. Quadrivalent HPV vaccine effectiveness against high‐grade cervical lesions by age at vaccination: A population‐based study.
FUNDAÇÃO OSWALDO CRUZ (FIOCRUZ). HPV, câncer de colo do útero e vacina: entenda a relação. 2014. Disponível em: https://portal.fiocruz.br/noticia/hpv-cancer-de-colo-do-utero-e-vacina-entenda-relacao. Acesso em: 12 set. 2022.
INSTITUTO NACIONAL DO CÂNCER (INCA). Câncer de colo de útero. 2020. Disponível em: https://www.inca.gov.br/tipos-de-cancer/cancer-do-colo-do-utero/profissional-de-saude. Acessado em: 17 de maio de 2020.
INSTITUTO NACIONAL DO CÂNCER (INCA). Câncer de colo de útero. 2022. Disponível em: https://www.inca.gov.br/tipos-de-cancer/cancer-do-colo-do-utero/profissional-de-saude. Acessado em: 01 de setembro de 2022.
JOURA EA, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. The New England Journal of Medicine, 2015; 372(8): 711-723.
LEI J, et al. Impact of HPV vaccination on cervical screening performance: a population-based cohort study. British Journal of Cancer, 2020; 123: 155-160.
LOPALCO PL. Spotlight on the 9-valent HPV vaccine. Drug Design, Development and Therapy. 2017; 11:35-44.
LUOSTARINEN T, et al. Vaccination protects against invasive HPV-associated cancers. Int. J. Cancer, 2018; 142(10): 2186-2187.
LUVISARO BMO. DETERMINANTES E IMPACTO DA VACINA CONTRA O HPV NA MORTALIDADE POR CÂNCER DO COLO UTERINO NO BRASIL. Dissertação (Mestrado), Universidade Federal de Minas Gerais, Belo Horizonte, 2018. 83p.
MARKOWITZ, LE. et al. Prevalência de HPV após a introdução do programa de vacinação nos Estados Unidos. Pediatrics, 2016; 137(3): e20151968.
MCLAUGHLIN-DRUBIN ME, MÜNGER K. Oncogenic activities of human papillomaviruses. Virus res, 2009; 143(2): 195-208.
MINISTÉRIO DA SAÚDE. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil, 2019; 120p.
MOURA LL, et al. Cobertura da vacina papilomavírus humano (HPV) no Brasil: heterogeneidade espacial e entre coortes etárias. Revista Brasileira de Epidemiologia [online]. 2021; v. 24.
NYGÅRD M, et al. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin. Vaccine Immunol, 2015; 22(8): 943-948.
OLUSOLA P, et al. Human papilloma virus-associated cervical cancer and health disparities. Cells, 2019; 8(6): 622.
RIBEIRO DV. O impacto da vacina contra o HPV no mundo: resultados iniciais e desafios. Universidade Federal de Santa Catarina, 2019; 31p.
SANTANA EA, et al. Câncer cervical: etiologia, diagnóstico e prevenção. Revista Arquivos de Ciências da Saúde, 2008: 15(4): 199-204.
SANTOS JGC, DIAS JMG. Vacinação pública contra o papilomavirus humano no Brasil. Revista Médica de Minas Gerais, 2018: (28): 1-7.
SCHIFFMAN M, et al. Human papillomavirus and cervical cancer. The Lancet, 2007; 370(9590): 890-907.
SEHNAL B, et al. Klinicka Onkologie: Casopis Ceske A Slovenske Onkologicke Spolecnosti. Klin Onkol, 2014; 27(4): 239-246.
SELLORS JW, SANKARANARAYANAN R. Colposcopia e tratamento da neoplasia intra-epitelial cervical: Manual para principiantes. França: Centro Internacional de Pesquisas sobre o Câncer, 2004; 145p.
SICHERO L, et al. The contribution of Latin American research to HPV epidemiology and natural history knowledge. Braz J Med Biol Res, 2020; 53(2).
SOCIEDADE BRASILEIRA DE IMUNIZAÇÕES (SBIM). Coberturas vacinais no Brasil são baixas e heterogêneas, mostram informações do PNI. 2020. Disponível em : https://sbim.org.br/noticias/1359-coberturas-vacinais-no-brasil-sao-baixas-e-heterogeneas-mostram-informacoes-do-pni. Acessado em: 03 de novembro de 2021.
SOW PS, et al. Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women. The Journal of Infectious Diseases, 2013; 207(11): 1753-1763.
VESIKARI T, et al. Um estudo randomizado, duplo-cego, de fase III da imunogenicidade e segurança de uma vacina de partícula semelhante ao vírus do papilomavírus humano L1 (V503) versus Gardasil® em meninas de 9-15 anos de idade. The Pediatric infectious disease jornal, 2015; 34(9): 992-998.
ZARDO GP, et al. Vacina como agente de imunização contra o HPV. Cien Saúde Colet, 2014; 19: 3799-3808.